Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
fluticasone furoate
vilanterol |
| gptkbp:administeredBy |
inhalation
|
| gptkbp:alsoKnownAs |
Breo Ellipta
|
| gptkbp:approvalYear |
2013
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:drugClass |
gptkb:long-acting_beta2-adrenergic_agonist
gptkb:Corticosteroid |
| gptkbp:form |
dry powder inhaler
|
| gptkbp:manufacturer |
GlaxoSmithKline
Theravance |
| gptkbp:marketedAs |
Relvar Ellipta
|
| gptkbp:marketedIn |
gptkb:Europe
gptkb:United_States |
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:usedFor |
asthma
chronic obstructive pulmonary disease |
| gptkbp:bfsParent |
gptkb:Mondovì,_Italy
|
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
Breo
|